SAB Biotherapeutics Warrant

SABSW

Market cap $104K

SABSW Hedge Fund Activity: Q1 2026 in Review

6 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2026, worth a combined $21.1K — up 152% from $8.34K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SABSW and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.

The largest buyer was LMR Partners, opening a new position worth an estimated $18.6K. The largest seller was UBS Group, cutting an estimated $69.

• 6 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2026, down from 7 in Q4 2025.
• Funds reported $21.1K of SAB Biotherapeutics Warrant stock for Q1 2026, up 152% quarter-over-quarter.
• 1 fund opened new SAB Biotherapeutics Warrant positions in Q1 2026 and 2 closed out, a net change of -1 holder.
• The largest SAB Biotherapeutics Warrant buyer in Q1 2026 was LMR Partners, an estimated $18.6K added.
• The largest SAB Biotherapeutics Warrant seller in Q1 2026 was UBS Group, an estimated $69 sold.

Based on aggregated 13F filings for Q1 2026.